The IKK Inhibitor II, Wedelolactone, also referenced under CAS 65646-68-6, controls the biological activity of IKK. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.
別名:
IKK Inhibitor II, Wedelolactone, Wedelolactone, Eclipta alba, 7-Methoxy-5,11,12-trihydroxy-coumestan
Cell-permeable. The naturally-occuring active ingredient from the herbal medicine, Eclipta alba, that acts as a selective and irreversible inhibitor of IKKα and IKKβ kinase activities (IC50<10 µM). Inhibits NF-κB-mediated gene transcription in cells by blocking the phosphorylation and degradation of IκBα. Does not affect the activities of p38 MAP kinase or Akt.
The naturally isolated active ingredient of the herbal medicine, Eclipta alba, that acts as a cell permeable, selective and irreversible inhibitor of IKKα and β kinase activity (IC50<10 µM). Inhibits NF-κB-mediated gene transcription in cells by blocking the phosphorylation and degradation of IκBα. Has no effects on p38 MAP kinase or Akt.
生物化学的/生理学的作用
Cell permeable: yes
Primary Target IKKα and β kinase activity
Product does not compete with ATP.
Reversible: no
Target IC50: <10 µM against IKKα and β kinase activity
包装
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
再構成
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
その他情報
Kobori, M., et al. 2004. Cell Death Differ.11, 123. Li, C.C., et al. 2003. J. Org. Chem.68, 8500. Mors, W.B., et al. 1989. Toxicon27, 1003. Wagner, H., and Fessler, B. 1986. Planta Med.5, 374.
法的情報
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Annals of clinical and translational neurology, 10(2), 246-265 (2022-12-28)
Neurodegeneration induced by inflammatory stress in multiple sclerosis (MS) leads to long-term neurological disabilities that are not amenable to current immunomodulatory therapies. Here, we report that neuronal downregulation of Splicing factor 3b subunit 2 (SF3B2), a component of U2 small